Every Form 4 that Acrivon Therapeutics, Inc. (ACRV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACRV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRV filings page.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Business Officer Michaela Levin received equity-based compensation on August 31, 2026. She was granted 130,000 options to buy common stock at an exercise price of $2.09 per share, expiring August 30, 2036, and 30,000 restricted stock units
Acrivon Therapeutics, Inc. (ACRV) reported that President and CEO Dr. Peter Blume-Jensen, who is also a director, and co-founder and EVP Business Operations Dr. Kristina Masson, also a director, filed a joint Form 4. On 2026-08-25, 14,036 shares of Common Stock were sold at a weighted average price of $2.2064 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. Following this transaction, Dr. Blume-Jensen held 2,230,052 shares directly, and there were 385,859 shares held indirectly through securities held by Dr. Masson. Each spouse disclaims beneficial ownership of the other’s reported holdings except to the extent of their pecuniary interest.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Accounting Officer Katharine Peterson sold 101 shares of common stock on 2026-08-18 at $2.01 per share. According to the company’s disclosure, these shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and she now holds 18,033 shares directly.
Acrivon Therapeutics, Inc. (ACRV) reported an insider transaction by Chief Legal Officer Mary Miller. On 2026-08-18, she sold 185 shares of common stock at $2.01 per share. The shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and she now holds 82,009 shares directly.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Development Officer Erick Gamelin had 400 shares of common stock sold on August 18, 2026 at $2.01 per share. According to the disclosure, these shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, leaving him with 52,592 shares held directly.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Operating Officer Eric Devroe had 604 shares of common stock sold on 2026-08-18 at $2.01 per share. According to the company, the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and Devroe now holds 146,349 shares directly.
Acrivon Therapeutics, Inc. (ACRV) reported insider transactions involving President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson. On 2026-08-18, a total of 1,713 shares of Common Stock were sold at $2.01 per share to satisfy a mandatory tax withholding requirement upon vesting of restricted stock units.
Of these, 1,229 shares were sold from shares held by Dr. Blume-Jensen, leaving 2,244,088 shares held directly. Another 484 shares were sold from shares held by Dr. Masson, leaving 385,859 shares held indirectly, with each spouse disclaiming beneficial ownership of the other’s securities except for their pecuniary interest.
Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported a sale of 1,142 shares of common stock on August 4, 2026 at $1.57 per share. The shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and he now directly holds 66,008 shares.
On 2026-07-21, Acrivon Therapeutics Chief Legal Officer Mary Miller had 573 shares of Common Stock sold at $1.76 per share. A note explains that the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units. She continues to hold 82,194 shares directly after the transaction.
Acrivon Therapeutics, Inc. reported that entities affiliated with RA Capital are associated with a new stock option grant linked to director Dr. Derek DiRocco. The derivative award covers 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests on the day before Acrivon’s next annual stockholder meeting, conditioned on Dr. DiRocco’s continued service. According to the disclosures, Dr. DiRocco holds the option for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, and any net value from exercise will offset advisory fees owed to RA Capital Management, L.P., while the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics director Michael John Tomsicek received a stock option grant covering 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares are reported as held directly after this grant. The filing states that these options will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided he remains in continuous service through that vesting date. This is a compensation-related award and does not reflect an open-market purchase or sale of shares.
Acrivon Therapeutics, Inc. director Sharon Shacham received a grant of stock options representing 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036.
All 20,275 option shares remain held following the transaction. According to the grant terms, these options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided Shacham continues to serve through that vesting date.
Acrivon Therapeutics director Palani Santhosh received a stock option grant for 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares remain held following the grant. The option will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, conditioned on Santhosh’s continuous service through that vesting date.
Acrivon Therapeutics director Ivana Magovcevic-Liebisch received a new stock option grant. She was granted options to acquire 20,275 shares of Acrivon Therapeutics common stock at an exercise price of $1.52 per share.
The options are a compensation-related award, not an open-market purchase. They vest on the date immediately preceding the company’s next annual meeting of stockholders, as long as she remains in continuous service through that vesting date. Following this grant, she holds stock options for 20,275 underlying shares directly.
Acrivon Therapeutics director Derek DiRocco was granted a stock option covering 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests immediately before Acrivon’s next annual stockholder meeting, subject to his continuous service.
The option is held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. Any net cash or stock from exercise must be turned over to RA Capital Management, L.P., and DiRocco disclaims beneficial ownership of the option and underlying shares.
Acrivon Therapeutics director Charles M. Baum received a grant of stock options for 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036. All 20,275 options will vest immediately before Acrivon’s next annual stockholder meeting, contingent on his continuous service.
Acrivon Therapeutics reported a routine insider equity adjustment involving its President and CEO, Dr. Peter Blume-Jensen, and EVP of Business Operations, Dr. Kristina Masson. The company withheld 13,729 shares of common stock at $1.79 per share to cover mandatory taxes upon the vesting of restricted stock units, a non‑market transaction classified as a tax-withholding disposition. Following this, Dr. Blume-Jensen directly holds 2,245,317 shares of common stock, and the filing also lists 386,343 shares of common stock as indirectly held between the spouses, with each disclaiming beneficial ownership beyond their pecuniary interest.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported a compensation-related equity award involving entities affiliated with RA Capital. Director Derek DiRocco received a grant of 9,366 restricted stock units (RSUs), each representing one share of common stock at a price of $0.00 per share. The RSUs vest in full on March 18, 2027, if he continues serving as a director through that date. Under his arrangement with RA Capital Management, L.P. as investment manager, Dr. DiRocco holds these RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. and must deliver any settled shares to the adviser to offset advisory fees. As of this filing, 426,302 shares of common stock are held indirectly by the Fund and 11,803,094 shares are held indirectly by Nexus Fund II. The reporting persons and related parties disclaim beneficial ownership of the RSUs and underlying common stock except to the extent of any pecuniary interest.
Acrivon Therapeutics, Inc. director Michael John Tomsicek reported an equity compensation grant. He acquired 9,366 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost. Each RSU represents one share, and the award vests in full on May 18, 2027, subject to his continuous service.
Shacham Sharon reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics director Sharon Shacham received an equity grant in the form of restricted stock units. The award covers 9,366 RSUs, each representing a right to receive one share of Acrivon common stock at no purchase price. These RSUs vest in full on May 18, 2027, provided she remains in continuous service through that date. Following this grant, her reported direct holdings total 9,366 shares.
Palani Santhosh reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics director Palani Santhosh reported an equity grant. He received 9,366 shares of Common Stock in the form of restricted stock units (RSUs), awarded as compensation rather than an open-market purchase. Each RSU represents a right to receive one share of Common Stock.
The RSUs will vest in full on May 18, 2027, if he continues to serve through that date. Following this grant, the filing shows 9,366 shares held directly, reflecting his entire reported position in this filing.
Acrivon Therapeutics, Inc. director Ivana Magovcevic-Liebisch received an equity award in the form of 9,366 restricted stock units of common stock. The award was granted at no cash cost to her and represents a compensation-related acquisition rather than an open-market purchase.
Each restricted stock unit gives her the right to receive one share of Acrivon common stock, but the units will vest in full only on May 18, 2027, provided she continues to serve the company through that date. Following this grant, her reported direct holding from this award is 9,366 shares, highlighting a single, time-based vesting grant rather than ongoing trading activity.
Acrivon Therapeutics director Derek DiRocco received a grant of 9,366 restricted stock units (RSUs) of Common Stock. The award was made as a grant or other acquisition at a price of $0.00 per share, leaving 9,366 shares reported as held after the transaction.
Each RSU represents a contingent right to receive one share of Acrivon Therapeutics, Inc. Common Stock and will vest in full on May 18, 2027, subject to continuous service through that date. Under DiRocco’s arrangement with RA Capital Management, L.P., he holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., must turn over any stock received upon settlement to RA Capital Management, and therefore disclaims beneficial ownership of these RSUs and the underlying common stock.
BAUM CHARLES M reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics director Charles M. Baum received an equity grant in the form of restricted stock units. The Form 4 reports an award of 9,366 shares of Common Stock at no purchase price, increasing his directly held stake to 9,366 shares.
The footnotes explain these are RSUs, each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on May 18, 2027, provided Baum remains in continuous service with the company through that vesting date.
Peterson Katharine reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that Chief Accounting Officer Katharine Peterson received a grant of 14,227 shares of Common Stock on May 18, 2026, at a stated price of $0.00 per share. According to the footnote, these shares are in the form of restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock.
Of these RSUs, 16.67% are scheduled to vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments afterward, subject to her continuous service through each vesting date. Following this award, Peterson directly holds 18,134 shares of Common Stock as reported in the filing.
Mirza Mansoor Raza reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that its Chief Medical Officer, Mirza Mansoor Raza, received an award of 38,817 shares of Common Stock in the form of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share, with 16.67% scheduled to vest on November 18, 2026 and the remaining units vesting in 10 substantially equal quarterly installments thereafter, subject to his continued service. After this grant, he is reported as directly holding 38,817 shares in this award.
Miller Mary reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics Chief Legal Officer Mary Miller received an equity award of 49,830 shares of Common Stock in the form of restricted stock units (RSUs). The grant was made at no cash cost to her and is compensation-related rather than an open-market transaction.
The RSUs vest over time. According to the terms, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments after that date, as long as she continues in service. Following this grant, she directly holds 82,767 shares of Common Stock.
Levy Adam D. reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received an equity compensation grant in the form of restricted stock units. He was awarded 46,167 RSUs of common stock at no cash cost, increasing his directly held shares to 67,150 after the grant.
Each RSU represents a contingent right to receive one share of common stock. According to the vesting schedule, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continuous service with the company.
Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that Chief Development Officer Erick Gamelin received an equity compensation grant in the form of restricted stock units. The award covers 38,584 shares of Common Stock at a stated price of $0.00 per share, reflecting a grant rather than a market purchase.
Each RSU represents a contingent right to receive one share of Common Stock. According to the vesting schedule, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continuous service. Following this grant, Gamelin directly holds 52,992 shares of Common Stock.
Devroe Eric reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that its Chief Operating Officer, Eric Devroe, received an equity award in the form of restricted stock units. On May 18, 2026, he was granted 72,981 shares of Common Stock at no cash cost as a compensation-related award.
These RSUs represent a contingent right to receive one share of Common Stock per unit. 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continued service. Following this award, Devroe directly holds 146,953 shares of Common Stock.
Acrivon Therapeutics, Inc. reported equity awards to senior leaders in the form of restricted stock units (RSUs) and common stock grants coded as acquisitions. One award covers 72,706 RSUs at a grant price of $0.00 per share, and another covers 180,095 shares of Common Stock at $0.00 per share.
Each RSU represents a contingent right to receive one share of Common Stock. Of the RSUs, 16.67% are scheduled to vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to the executive’s continuous service. After these grants, one indirect holding totals 386,343 shares and one direct holding totals 2,259,046 shares, with certain shares held by each executive’s spouse and the non-holding spouse disclaiming beneficial ownership except for any pecuniary interest.
Acrivon Therapeutics Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 99 shares of common stock were withheld by the company at a value of $1.92 per share to cover mandatory tax withholding. After this non-market transaction, she directly holds 3,907 common shares.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine tax-related share disposition. On May 14, 2026, 184 shares of common stock were withheld at $1.92 per share to cover mandatory tax obligations upon the vesting of restricted stock units. After this withholding, she directly holds 32,937 shares of Acrivon common stock. This was not an open-market sale and reflects standard tax withholding mechanics rather than a discretionary trade.
Acrivon Therapeutics Chief Development Officer Erick Gamelin reported a routine tax-related share disposition. On the vesting of restricted stock units, 404 shares of common stock were withheld by the company at $1.92 per share to satisfy mandatory tax withholding obligations. After this withholding, Gamelin directly holds 14,408 shares of Acrivon common stock.
Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe had 613 shares of Common Stock withheld on May 14, 2026 to cover mandatory tax obligations tied to the vesting of restricted stock units. The shares were valued at $1.92 per share for this tax-withholding disposition, which is an administrative mechanism rather than an open-market sale. Following this event, Devroe holds 73,972 Common Stock shares directly, indicating he retains essentially his full equity position while satisfying the required tax liability.
Acrivon Therapeutics executives reported routine tax-related share dispositions tied to restricted stock unit vesting. A total of 1,743 common shares at $1.92 were withheld by the company to satisfy mandatory tax obligations, rather than sold in the open market.
After these withholdings, one executive directly holds 2,078,951 shares and another has 313,637 shares reported as indirectly held through spousal ownership, reflecting that both retain substantial positions following the transactions.
Acrivon Therapeutics, Inc. reported that investment entities affiliated with RA Capital acquired additional common stock through a grant or similar award. On the reported date, these entities indirectly obtained 3,888,888 shares of common stock at $1.80 per share, bringing one aggregated indirect position to 11,803,094 shares following the transaction. Another indirect holding line shows 426,302 shares after the same date. The filing notes that RA Capital Management, L.P., its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine tax-related share disposition. On the vesting of restricted stock units, 558 shares of common stock were withheld by the company at $1.78 per share to satisfy mandatory tax withholding obligations.
After this withholding, Miller directly holds 33,121 shares of Acrivon common stock. The filing shows no open-market purchases or sales, only this non-discretionary tax-withholding event tied to equity compensation.
Acrivon Therapeutics, Inc. reported that its Chief Accounting Officer, Katharine Peterson, received a grant of stock options covering 31,900 shares of common stock. The options were awarded on March 1, 2026 at an exercise price of $0.00 per share as a form of equity compensation.
According to the vesting terms, 25% of the option shares vest on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments after that date. Vesting in all cases requires Ms. Peterson to remain in continuous service through each vesting date.
Acrivon Therapeutics Chief Medical Officer Mirza Mansoor Raza received a grant of stock options covering 174,068 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase. According to the vesting schedule, 25% of the shares vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service through each vesting date. Following this award, he holds options on 174,068 shares directly.
Miller Mary reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics reported that Chief Legal Officer Mary Miller received a grant of stock options covering 129,760 shares of common stock on March 1, 2026. According to the vesting terms, 25% of these options vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, all conditioned on her continued service through each vesting date.
Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received a grant of stock options. The award covers 132,925 options with an exercise price of $0.00 per share, characterized as a grant or award acquisition rather than an open-market purchase.
According to the vesting terms, 25% of the options vest on March 1, 2027, and the remaining options vest in 36 substantially equal monthly installments after that date. All vesting requires Mr. Levy to remain in continuous service with the company through each vesting date.
Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics granted Chief Development Officer Erick Gamelin a stock option covering 94,946 shares of common stock. The award is reported as a direct beneficial holding at a stated price of $0.0000 per option unit.
According to the vesting terms, 25% of the shares subject to the option vest on March 1, 2027. The remaining shares vest in 36 substantially equal monthly installments after that date, conditioned on Gamelin’s continuous service through each vesting date.
Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe received a grant of stock options covering 186,728 shares of common stock. The Form 4 classifies this as a grant or award acquisition, not an open-market purchase or sale.
According to the vesting terms, 25% of the option vests on March 1, 2027, and the remaining shares vest in 36 substantially equal monthly installments thereafter, provided Devroe remains in continuous service through each vesting date.
Acrivon Therapeutics reported stock option awards to senior executives. The filing shows grants covering 417,210 options and 185,495 options, with exercise rights structured as long-term incentives rather than cash purchases. Twenty-five percent of each grant vests on March 1, 2027, and the remaining options vest in 36 equal monthly installments, conditioned on continued service. Footnotes explain that President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson each hold options and disclaim beneficial ownership of their spouse’s securities except for any economic interest.
Acrivon Therapeutics reported an insider tax-related share disposition involving its President and CEO, Dr. Peter Blume-Jensen. The company withheld 14,265 shares of common stock at $1.53 per share to cover mandatory taxes due on vested restricted stock units, rather than an open-market sale. After this withholding, Dr. Blume-Jensen directly holds 2,080,204 common shares. The filing also notes 314,127 common shares held indirectly in spousal accounts shared between Dr. Blume-Jensen and co-founder and EVP Dr. Kristina Masson, with each spouse disclaiming beneficial ownership beyond their economic interest.
Acrivon Therapeutics, Inc. Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 116 shares of common stock were withheld by the company to satisfy mandatory tax withholding, valued at $1.63 per share. After this withholding, Peterson directly holds 4,006 shares of Acrivon common stock.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine share disposition related to taxes. On the transaction date, 217 shares of common stock were withheld by the company at a price of $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. After this tax-withholding disposition, she held 33,679 shares of common stock directly.
Acrivon Therapeutics, Inc. Chief Development Officer Erick Gamelin reported a tax-related share disposition. On February 14, 2026, the issuer withheld 471 shares of common stock at $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. This reduced Gamelin’s directly held common stock to 14,812 shares. The transaction is classified as a disposition for tax withholding, not an open-market purchase or sale.
Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a small tax-related share disposition. On the vesting of restricted stock units, 723 shares of common stock were withheld by the company at a price of $1.63 per share to cover mandatory tax withholding. After this non-market transaction, Devroe directly holds 74,585 shares of Acrivon Therapeutics common stock.